Anchored in research undertaken and originally patented at Duke, Celldom is working on high throughput screening that allows the manipulation of single cells: massively parallel single cell pharmacogenomics with th e objective of computerizing biology by unmasking cellular heterogeneity. This platform has immediate touch-points in drug discovery and development, and future clinical applications. Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The companys TrapTx Analyzer System uniquely integrates both phenotypic and genomic data at massive scale -- up to tens of thousands of cells per experiment -- to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology
